Bioinspired extracellular vesicle-coated silica nanoparticles as selective delivery systems.

Bioinspired nanocarriers Extracellular vesicles Nanoparticles Selective targeting

Journal

Materials today. Bio
ISSN: 2590-0064
Titre abrégé: Mater Today Bio
Pays: England
ID NLM: 101757228

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 27 06 2023
revised: 25 10 2023
accepted: 26 10 2023
medline: 29 11 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: epublish

Résumé

In recent years, there has been a breakthrough in the integration of artificial nanoplatforms with natural biomaterials for the development of more efficient drug delivery systems. The formulation of bioinspired nanosystems, combining the benefits of synthetic nanoparticles with the natural features of biological materials, provides an efficient strategy to improve nanoparticle circulation time, biocompatibility and specificity toward targeted tissues. Among others biological materials, extracellular vesicles (EVs), membranous structures secreted by many types of cells composed by a protein rich lipid bilayer, have shown a great potential as drug delivery systems themselves and in combination with artificial nanoparticles. The reason for such interest relays on their natural properties, such as overcoming several biological barriers or migration towards specific tissues. Here, we propose the use of mesoporous silica nanoparticles (MSNs) as efficient and versatile nanocarriers in combination with tumor derived extracellular vesicles (EVs) for the development of selective drug delivery systems. The hybrid nanosystems demonstrated selective cellular internalization in parent cells, indicating that the EV targeting capabilities were efficiently transferred to MSNs by the developed coating strategy. As a result, EVs-coated MSNs provided an enhanced and selective intracellular accumulation of doxorubicin and a specific cytotoxic activity against targeted cancer cells, revealing these hybrid nanosystems as promising candidates for the development of targeted treatments.

Identifiants

pubmed: 38024844
doi: 10.1016/j.mtbio.2023.100850
pii: S2590-0064(23)00310-1
pmc: PMC10643352
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100850

Informations de copyright

© 2023 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Cells. 2023 Feb 19;12(4):
pubmed: 36831326
Nat Rev Drug Discov. 2021 Feb;20(2):101-124
pubmed: 33277608
Nanoscale. 2015 Apr 21;7(15):6471-80
pubmed: 25804371
RSC Adv. 2018 Jun 7;8(37):20862-20871
pubmed: 35542325
Oncotarget. 2016 Aug 2;7(31):49998-50016
pubmed: 27374178
Pharmaceutics. 2020 Dec 01;12(12):
pubmed: 33271883
Adv Healthc Mater. 2015 Aug 5;4(11):1645-52
pubmed: 25960053
ACS Omega. 2020 Jun 30;5(27):16701-16710
pubmed: 32685837
Acta Biomater. 2023 Feb;157:395-407
pubmed: 36476646
Drug Deliv. 2022 Dec;29(1):2621-2631
pubmed: 35941835
J Biol Chem. 2016 Sep 16;291(38):20055-67
pubmed: 27462074
Theranostics. 2020 Feb 10;10(8):3474-3487
pubmed: 32206102
Nanoscale Horiz. 2020 Sep 1;5(9):1293-1302
pubmed: 32608425
Nat Biotechnol. 2015 Sep;33(9):941-51
pubmed: 26348965
Chem Soc Rev. 2022 Jul 4;51(13):5365-5451
pubmed: 35642539
Drug Deliv Transl Res. 2023 Mar;13(3):716-737
pubmed: 36417162
Acta Biomater. 2021 Dec;136:570-581
pubmed: 34551333
Nanoscale Res Lett. 2020 May 20;15(1):115
pubmed: 32436107
Int J Hyperthermia. 2015;31(5):498-506
pubmed: 25955015
Sci Rep. 2019 Oct 25;9(1):15329
pubmed: 31653931
Cells. 2022 Jan 18;11(3):
pubmed: 35159126
ACS Nano. 2021 Nov 23;15(11):17080-17123
pubmed: 34699181
Nat Mater. 2013 Nov;12(11):991-1003
pubmed: 24150417
Cells. 2019 Nov 13;8(11):
pubmed: 31766144
J Mater Sci Mater Med. 2018 May 8;29(5):65
pubmed: 29737405
J Extracell Vesicles. 2023 Aug;12(8):e12352
pubmed: 37525398
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
ACS Appl Mater Interfaces. 2021 Mar 3;13(8):9656-9666
pubmed: 33596035
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
Nano Today. 2019 Apr;25:85-98
pubmed: 31360214
Eur J Pharm Biopharm. 2019 Dec;145:27-34
pubmed: 31629787
J Nanobiotechnology. 2022 Jan 21;20(1):45
pubmed: 35062958
Angew Chem Int Ed Engl. 2018 May 22;57(21):6049-6053
pubmed: 29480962
ACS Nano. 2016 Sep 27;10(9):8325-45
pubmed: 27419663
ACS Appl Mater Interfaces. 2017 Jul 12;9(27):22235-22251
pubmed: 28608695
Nanomicro Lett. 2019 Nov 16;11(1):100
pubmed: 34138027
Biology (Basel). 2020 Nov 18;9(11):
pubmed: 33218092
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2298-2305
pubmed: 31174440
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Nano Lett. 2019 Nov 13;19(11):7836-7844
pubmed: 31597431
Nano Lett. 2005 Feb;5(2):281-5
pubmed: 15794611

Auteurs

Bianca Dumontel (B)

Department of Chemistry in Pharmaceutical Sciences, School of Pharmacy, Institute Hospital 12 de Octubre (imas12), Universidad Complutense de Madrid, UCM, Madrid, 28040, Spain.

Carla Jiménez-Jiménez (C)

Department of Chemistry in Pharmaceutical Sciences, School of Pharmacy, Institute Hospital 12 de Octubre (imas12), Universidad Complutense de Madrid, UCM, Madrid, 28040, Spain.
Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, 28029, Spain.

María Vallet-Regí (M)

Department of Chemistry in Pharmaceutical Sciences, School of Pharmacy, Institute Hospital 12 de Octubre (imas12), Universidad Complutense de Madrid, UCM, Madrid, 28040, Spain.
Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, 28029, Spain.

Miguel Manzano (M)

Department of Chemistry in Pharmaceutical Sciences, School of Pharmacy, Institute Hospital 12 de Octubre (imas12), Universidad Complutense de Madrid, UCM, Madrid, 28040, Spain.
Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, 28029, Spain.

Classifications MeSH